FDA proposes a framework for accelerating personalized treatments for rare diseases

The United States Food and Drug Administration (FDA) has announced a new framework aimed at accelerating approvals for personalized treatments for rare genetic diseases. This proposal allows drug manufacturers to rely on small, well-controlled studies instead of traditional clinical trials when those are not feasible. The goal is to provide patients with early access to treatments, even when available data is limited, with ongoing safety monitoring through post-approval requirements.

The FDA will provide clearer rules for the development of drugs based on genome and RNA editing, requiring justifications for the absence of randomized studies and the collection of evidence in real-world conditions after approval. Manufacturers will need to complete confirmatory studies and ensure patient protection, including informed consent. The new framework will initially apply to therapies based on genetic editing but could also be extended to other personalized products. The FDA anticipates an increase in applications for treatments aimed at rare diseases, maintaining unchanged manufacturing standards but allowing for faster action based on previous experiences.